Patents Issued in September 25, 2018
-
Patent number: 10080715Abstract: The invention relates to a process for preparing polysaccharide-based microparticles with improved mechanical properties and hydrolytic stability. The spherical particles are useful as exfoliating agents in cosmetic formulations, in replacement of the newly banned plastic microbeads. The method comprises the preparation of hydrogel particles, drying of the particles, and a solid-state reaction that results in the covalent stabilization of the material. The invention also encompasses microparticles made using the method.Type: GrantFiled: April 18, 2017Date of Patent: September 25, 2018Assignee: Bowling Green State UniversityInventors: Giuseppe Giammanco, Alexis Ostrowski
-
Patent number: 10080716Abstract: A packaging unit (kit of parts) for dyeing keratin fibers and related methods. The packaging unit includes, formulated separately from one another, at least one container (C1), comprising a cosmetic agent (M1), which comprises at least one compound, selected from oxidation dye precursors, direct dyes and the mixtures thereof, and at least one aminated silicone polymer, comprising at least one structural unit of formula (I) and at least one structural unit of formula (II) where a denotes a linear or branched C4 to C8 alkyl group; and n denotes integers from 1 to 4. The kit further comprises at least one container (C2) including an oxidizing agent preparation (M2), which, in a cosmetically compatible carrier, comprises at least one oxidizing agent in a total amount of 0.5 to 15 wt. % based on the total weight of the oxidizing agent preparation.Type: GrantFiled: March 9, 2017Date of Patent: September 25, 2018Assignee: Henkel AG & Co. KGaAInventors: Sylvia Kerl, Susanne Bietz
-
Patent number: 10080717Abstract: An improved composition of hair oil for stimulation of hair growth, control of hair fall, dandruff and infections thereof. The composition of hair oil comprising active ingredients of Capric Caprylic Tri-Glycerides (CCTG), Mineral oil, Coconut Oil, Ylang Ylang Oil, Di-propylene Glycol, Centella Asiatica Extract and Butylated Hydroxy Toulene. The composition of hair oil supports the hair growth and relaxation of the scalp. The composition of hair oil also effectively reduces/remove dandruff and thereby control hair fall in the subject (e.g., not limiting to male/female human). The composition of hair oil additionally demonstrates the properties of cooling effect, darkening of hair and promotion of hair upon continuous use of the hair oil by the subjects. The proposed composition is alternatively used to reduce/remove Psoriasis.Type: GrantFiled: September 22, 2016Date of Patent: September 25, 2018Assignee: Indfrag Biosciences Inc.Inventors: Philip Samuel, Boobalarasu Nadar, Roshni Raj
-
Patent number: 10080718Abstract: The present invention relates generally to a methods of treating ear infections and clearing excess fluid from Eustachian tubes.Type: GrantFiled: September 1, 2011Date of Patent: September 25, 2018Assignee: TRY THIS FIRST, INC.Inventor: Scott Morehouse
-
Patent number: 10080719Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: GrantFiled: July 6, 2016Date of Patent: September 25, 2018Assignee: ALK-ABELLÓ A/SInventors: Henrik Hugo Jacobi, Annette Roemmelmayer Lundegaard, Christian Gauguin Houghton, Stig Aasmul-Olsen, Lise Lund Maerkedahl, Jan Sondergaard Andersen
-
Patent number: 10080720Abstract: The present invention is a technical filed of pharmaceutical preparation agent, and more particular to a pharmaceutical composition containing docetaxe. The pharmaceutical composition containing docetaxe includes docetaxel and a polyethylene glycol methyl ether-polylactide block copolymer with amino acid end groups. The advantage of the present invention is subjected to a tri-block copolymer with low toxicity as the drug carrier. In addition to the pharmaceutical active ingredients and carrier, there is no other additive in pharmaceutical composition containing docetaxe. Thus, the prescription is simpler and the security is higher. In pharmaceutical component containing docetaxel, docetaxel content is more than 20%, such that the preparation process of pharmaceutical component containing docetaxel is simple, and easy for the industrial applications.Type: GrantFiled: July 14, 2015Date of Patent: September 25, 2018Assignees: GAINIA (SHANGHAI) PATENT TECHNOLOGY LTD., POLYMER CHEMICAL CO. LTD.Inventor: Xin Teng
-
Patent number: 10080721Abstract: The invention relates to a hot-melt extruded pharmaceutical dosage form with controlled release of a pharmacologically active ingredient (A) embedded in a matrix comprising a polymer (C), the dosage form exhibiting a breaking strength of at least 300 N and having an oblong shape comprising a longitudinal direction of extension, a transversal direction of extension orthogonal to the longitudinal direction of extension, a front side, an opposite back side and a circumferential rim between said front and back side; wherein the core of the pharmaceutical dosage form has a morphological orientation caused by hot-melt extrusion that is substantially orthogonal to the longitudinal direction of extension of the dosage form; and/or the release per area of the pharmacologically active ingredient (A) through the front side and the opposite back side is faster than the release through the circumferential rim.Type: GrantFiled: July 21, 2010Date of Patent: September 25, 2018Assignee: GRUENENTHAL GMBHInventors: Lutz Barnscheid, Eric Galia
-
Patent number: 10080722Abstract: This invention provides a solid oral formulation including a capsule filling surrounded by an iron sugar shell so that the iron sugar shell makes at least some elemental iron content available for gastrointestinal absorption relative to the capsule filling while counteracting at least some of the constipation associated with oral iron consumption, and further includes methods of administering the solid oral formulation.Type: GrantFiled: November 14, 2017Date of Patent: September 25, 2018Inventor: Jugal K. Taneja
-
Patent number: 10080723Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.Type: GrantFiled: February 13, 2015Date of Patent: September 25, 2018Assignee: Pfizer Inc.Inventors: Maria Figueiredo, Erick Peeke, David Dewitt, Christina Van Geen Hoven, Greg Troiano, James Wright, Young-ho Song, Hong Wang
-
Patent number: 10080724Abstract: The present invention relates to a method for producing a medicament dosage form which consists of at least one piece which in each case comprises at least one medicament and at least one additive, the medicament and the additive being mixed and extruded from a die as a strand and the strand being cut into pieces of precise weight. The invention additionally relates to a device.Type: GrantFiled: March 11, 2014Date of Patent: September 25, 2018Assignee: GRÜNENTHAL GMBHInventors: Elisabeth Arkenau-Marić, Johannes Bartholomäus, Dieter Schateikis, Kai-Uwe Ustorf
-
Patent number: 10080725Abstract: Synthetically-derived S,S-heterodisubstituted disulfides that exhibit potent in vitro antibacterial activity against a variety of bacteria, including Staphylococcus aureus, methicillin-resistant Staphylococcus aureus and Francisella tularensis. The present invention provides compounds, methods and compositions effective to treat microbial/bacterial infections, and, especially, infections arising from bacteria which have developed resistance to conventional antibiotics.Type: GrantFiled: November 11, 2016Date of Patent: September 25, 2018Assignee: University of South FloridaInventors: Edward Turos, Praveen Ramaraju
-
Patent number: 10080726Abstract: The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of hyperhidrosis.Type: GrantFiled: August 20, 2015Date of Patent: September 25, 2018Inventor: Merouane Bencherif
-
Patent number: 10080727Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.Type: GrantFiled: July 12, 2017Date of Patent: September 25, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10080728Abstract: The invention relates to medicine, namely, to the solutions used for hemostasis. The hemostatic agent, which represents a polyammonia methanediamine chloride of the general formula where: n=1-20, m=1-10, at that n×m?8. The hemostatic agent may be applied in the form of a 0.01-10% aqueous solution. An aqueous solution of the preparation can be used for impregnation of materials used for bleeding arrest, suture material, bandaging material. The hemostatic agent may be used in the composition of a retraction cord, adhesive pastes, vaginal and rectal suppositories, creams, gels, as well as used with microchips that provide slow release of the preparation. The preparation can also be used in eye drops, eye ointments, and lubricants applied to the surface of the catheter. The drug can be used in endodontic treatment, may be injected into a polymer sealer for root canal obturation, as well as locally—by means of electrophoresis.Type: GrantFiled: April 20, 2015Date of Patent: September 25, 2018Inventors: Viktor Veniaminovich Tets, Georgy Viktorovich Tets
-
Patent number: 10080729Abstract: The present invention relates to intervertebral misalignment, such as scoliosis, spondylolisthesis, vertebral subluxation and vertebral fractures. A composition for use in the treatment of intervertebral misalignment is provided. The composition comprises lactic acid, or a pharmaceutically acceptable salt thereof. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.Type: GrantFiled: March 17, 2016Date of Patent: September 25, 2018Assignee: STAYBLE THERAPEUTICS ABInventor: Kjell Olmarker
-
Patent number: 10080730Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.Type: GrantFiled: January 8, 2014Date of Patent: September 25, 2018Assignee: United Therapeutics CorporationInventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
-
Patent number: 10080732Abstract: A method of stimulating ventilatory and/or respiratory drive in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising a cystine ester or a pharmaceutically acceptable salt thereof. Embodiments described herein relate to compositions and methods of stimulating ventilatory and/or respiratory drive in a subject in need thereof, and particularly relates to compositions and methods of treating breathing diseases and/or disorders associated with impaired ventilatory and/or respiratory drive.Type: GrantFiled: January 13, 2016Date of Patent: September 25, 2018Assignee: Case Western Reserve UniversityInventors: Benjamin Gaston, Stephen Lewis
-
Patent number: 10080733Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.Type: GrantFiled: October 12, 2017Date of Patent: September 25, 2018Assignee: Alkermes Pharma Ireland LimitedInventors: Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
-
Patent number: 10080734Abstract: A method for treating autism and other neurodevelopmental disorders including the step of administering an effective amount of an isothiocyanate functional surfactant to a human, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. The administration of the isothiocyanate functional surfactant may be augmented with a NMDA-receptor antagonist and/or a TNF-? inhibiting agent.Type: GrantFiled: October 24, 2017Date of Patent: September 25, 2018Assignee: The William M. Yarbrough foundationInventor: Michael E. Silver
-
Patent number: 10080735Abstract: The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.Type: GrantFiled: September 22, 2017Date of Patent: September 25, 2018Assignee: Olatec Therapeutics LLCInventor: Joseph St. Laurent
-
Patent number: 10080736Abstract: The present invention relates to cannabinoid compositions. These compositions can be encapsulated (e.g., microencapsulated). In particular, these compositions can be administered to a subject, such as through oral consumption or topical treatment.Type: GrantFiled: March 7, 2017Date of Patent: September 25, 2018Assignee: OJAI ENERGETICS PBCInventors: William Kleidon, Justin Kirkland
-
Patent number: 10080737Abstract: Polymer conjugates characterized in that the backbone of the polymer is an anionic polymer and hydrophobic moieties are covalently attached to the polymer backbone are useful for preparing drug encapsulated polymer hydrotropes and compositions. Such materials are useful in methods for delivering the drug into cells, and for the treatment and alleviation of diseases and disorders such as cancer.Type: GrantFiled: April 6, 2015Date of Patent: September 25, 2018Assignee: Nitto Denko CorporationInventors: Wenbin Ying, Kwok Yin Tsang, Hao Bai, Haiqing Yin, Jihua Liu, Li Wang
-
Patent number: 10080738Abstract: A method for producing a patch comprising a support layer and an adhesive agent layer comprises: a mixture preparation step of mixing asenapine or a pharmaceutically acceptable salt thereof with sodium acetate whose particle diameter D50 at a cumulative volume of 50% in a particle diameter distribution is 40 to 1000 ?m, in such a manner that the sodium acetate and sodium diacetate generated from the sodium acetate have a particle diameter D50 of 10 ?m or smaller, thereby obtaining a mixture containing the sodium diacetate and the asenapine or pharmaceutically acceptable salt; and an adhesive-agent-layer formation step of forming the adhesive agent layer comprising the sodium diacetate, the asenapine or pharmaceutically acceptable salt, and a pressure-sensitive adhesive base agent, by using an adhesive agent layer composition obtained by mixing the mixture with the pressure-sensitive adhesive base agent.Type: GrantFiled: October 24, 2016Date of Patent: September 25, 2018Assignee: HISAMITSU PHARMACEUTICAL CO., LTD.Inventors: Masayuki Suzuki, Hiroaki Okutsu, Takashi Yasukochi, Yasunori Takada
-
Patent number: 10080739Abstract: Therapeutically effective 2,4,5-trisubstituted imidazole compounds are provided. Also provided are methods of preparing the compounds and pharmaceutical compositions comprising the compounds alone or in combination with other agents.Type: GrantFiled: January 22, 2015Date of Patent: September 25, 2018Assignee: Aptose Biosciences Inc.Inventors: Mario Huesca, Raed Al-Qawasmeh, Aiping H. Young, Yoon Lee, Lisa Lock
-
Patent number: 10080740Abstract: The present invention provides methods for treating a cancer in a subject and for inhibiting tumor growth, metastasis or a dihydrorotate oxygenase enzyme activity of a tumor or cancer cell. At least one trisubstituted benzotriazole derivative with the formula (I) is administered to the subject or is contacted with the cancer cell. Compounds of formula (I) have substituents R1, R2 and R3 which have the meanings given in the specification, and pharmaceutically acceptable salts thereof.Type: GrantFiled: September 28, 2017Date of Patent: September 25, 2018Assignee: Aurigene Discovery Technologies LimitedInventors: Siva Sanjeeva Rao Thunuguntla, Subramanya Hosahalli, Satish Reddy Kunnam
-
Patent number: 10080741Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.Type: GrantFiled: April 26, 2017Date of Patent: September 25, 2018Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Brett Granger, Ruichao Shen, Xuechao Xing, Bin Wang, Jun Ma, Jing He, Jiang Long, Yong He, Guoqiang Wang
-
Patent number: 10080742Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.Type: GrantFiled: April 26, 2017Date of Patent: September 25, 2018Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Ruichao Shen, Xuechao Xing, Brett Granger, Bin Wang, Jun Ma, Jing He, Yong He, Jiang Long, Guoqiang Wang
-
Patent number: 10080743Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.Type: GrantFiled: April 26, 2017Date of Patent: September 25, 2018Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Bin Wang, Xuechao Xing, Ruichao Shen, Brett Granger, Jun Ma, Jing He, Yong He, Jiang Long, Guoqiang Wang
-
Patent number: 10080744Abstract: The present invention comprises compounds of Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and {circle around (A)} are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.Type: GrantFiled: November 14, 2017Date of Patent: September 25, 2018Assignee: Janssen Pharmaceutica NVInventors: Steven Goldberg, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
-
Patent number: 10080745Abstract: Described herein are assays for identifying piericidins and piericidin compositions.Type: GrantFiled: November 24, 2014Date of Patent: September 25, 2018Assignee: The Regents of the University of California Santa CruzInventors: Victoria Auerbuch Stone, Roger G. Linington, Weng Ruh Wong, Miles C. Duncan
-
Patent number: 10080746Abstract: The present invention relates to a donepezil derivative of general formula (I) or a pharmaceutically acceptable salt thereof, wherein R in the formula is as disclosed herein; and a method for preparation thereof; and a composition comprising an effective amount of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to use of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof in preparing a medicament for treating a disease resulted from an abnormality in acetylcholinesterase activity.Type: GrantFiled: November 26, 2015Date of Patent: September 25, 2018Assignee: NORATECH PHARMACEUTICALS, INC.Inventors: Fei Liu, Cuixia Zhang, Chenggang Lin, Chunyan Zhou, Pan Chen, Wei Wang, Lulu Wang
-
Patent number: 10080747Abstract: The present invention relates to methods of treating and/or ameliorating the severity of inflammation and autoimmunity in the central nervous system (CNS). In one embodiment, the present invention provides a method of treating multiple sclerosis by administering a therapeutically effective dosage of nicotine, or a pharmaceutical equivalent, analog, derivative, or salt thereof.Type: GrantFiled: January 5, 2017Date of Patent: September 25, 2018Assignee: Dignity HealthInventors: Fu-Dong Shi, Ronald J. Lukas, Timothy Vollmer
-
Patent number: 10080748Abstract: The present invention provides methods of attenuating or preventing brain injury mediated damage in the central nervous system by attenuating or preventing leukotriene-mediated events following a brain injury or long-term neuroinflammation after brain injury, in Alzheimer's disease, multiple sclerosis, stroke, and post-traumatic stress disorder. The methods comprise administering at least one 5-lipoxygenase activating protein (FLAP) inhibitor either before or after the brain injury. The method finds use in the treatment of traumatic brain injury (TBI), stroke, multiple sclerosis, Alzheimer's disease, post-traumatic stress disorder and other brain injuries associated with production of leukotrienes in the central nervous system. Preferably the FLAP inhibitor is administered intranasally and preferably for certain high risk individuals prophylactically prior to any potential brain injury event.Type: GrantFiled: February 4, 2015Date of Patent: September 25, 2018Assignee: Bioscience Pharma Partners, LLCInventors: Kim A. Heidenreich, Robert C. Murphy
-
Patent number: 10080749Abstract: The present invention is directed to methods of treating tuberculosis by providing a pharmaceutically effective amount of a combination of drug compounds.Type: GrantFiled: November 3, 2015Date of Patent: September 25, 2018Assignee: The Regents of the University of CaliforniaInventors: Chih-Ming Ho, Daniel L. Clemens, Bai-Yu Lee Clemens, Marcus Aaron Horwitz, Aleidy Marlene Silva Vite, Theodore Kee, Xianting Ding
-
Patent number: 10080750Abstract: The invention provides novel heterocyclic amine compounds according to Formula (I) and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.Type: GrantFiled: April 18, 2017Date of Patent: September 25, 2018Assignee: Merck Patent GmbHInventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Lizbeth C. Deselm, Hui Qiu, Yufang Xiao, Constantin Neagu, Igor Mochalkin, Theresa L. Johnson
-
Patent number: 10080751Abstract: Therapeutic methods, kits, dosing regimens and uses of a medicament comprising iclaprim are provided, for example, for the treatment of bacterial infection. The administration of iclaprim in a fixed amount can achieve a Cmax(ss) below about 800 ng/mL, a T>MIC of between about 30% to about 95% and a ratio of AUC/MIC of about 20 to about 85, and the bacterial infection can be treated. The fixed amount can be about 70 mg to about 100 mg. The bacterial infection treated may be caused, or related to, drug-resistant bacteria including S. pneumoniae, H. influenzae, S. aureus, K. pneumoniae and M. catarrhalis. The bacterial infection may manifest as a skin and skin structure infection, pneumonia, asthma, emphysema and/or other adverse pulmonary conditions.Type: GrantFiled: May 4, 2017Date of Patent: September 25, 2018Assignee: Motif Biosciences Inc.Inventor: David Huang
-
Patent number: 10080752Abstract: The present invention provides methods for treating tumors of the brain by administering the compounds of the Formula A and particularly N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment. In the methods of the invention, the compounds disclosed herein were surprisingly found to cross the blood brain barrier. The method of the present invention further relates to the treatment of cancers of any type potentially responding to EGFR, HER2, VEGFR2, or Src family kinase inhibitors and that are found in the brain.Type: GrantFiled: March 10, 2015Date of Patent: September 25, 2018Assignee: KADMON CORPORATION, LLCInventor: Samuel Waksal
-
Patent number: 10080753Abstract: The invention provides novel heterocyclic carboxamide compounds according to Formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.Type: GrantFiled: August 3, 2016Date of Patent: September 25, 2018Assignee: Merck Patent GmbHInventors: Bayard R. Huck, Xiaoling Chen, Yufang Xiao, Ruoxi Lan, Lizbeth Celeste De Selm, Constantin Neagu, Justin Potnick, Srinivasa R. Karra, Theresa L Johnson
-
Patent number: 10080754Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.Type: GrantFiled: December 8, 2016Date of Patent: September 25, 2018Assignee: Boehringer Ingelheim International GmbHInventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
-
Patent number: 10080755Abstract: This invention relates to deuterated analogs of etifoxine of Formula 1, solvates, prodrugs, and pharmaceutically acceptable salts thereof, as well as to methods for their preparation and use, and to pharmaceutical compositions. Briefly, this invention is generally directed to deuterated analogs of etifoxine as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same.Type: GrantFiled: March 18, 2016Date of Patent: September 25, 2018Assignee: ANVYL, LLCInventor: Olivier Dasse
-
Patent number: 10080756Abstract: Disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I: or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma, or a solid tumor cancer, such as pancreatic, lung and colon cancer.Type: GrantFiled: June 14, 2017Date of Patent: September 25, 2018Assignee: Gilead Sciences, Inc.Inventors: Julie Di Paolo, Astrid Clarke
-
Patent number: 10080757Abstract: Compounds and salts thereof which are acyl-sulfonamides or certain carboxylic acids and which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include 2-aminothiazoles and triazolothiadiazines, particularly 3,6,7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 2-amino and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium, for example, M. tuberculosis and M. smegmatis and Klebsiella, for example, Klebsiella pneumoniae. Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.Type: GrantFiled: March 13, 2017Date of Patent: September 25, 2018Inventors: Laura Lee Kiessling, Valerie Jean Winton, Alexander Mark Justen
-
Patent number: 10080758Abstract: The present invention provides a tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide.Type: GrantFiled: January 22, 2016Date of Patent: September 25, 2018Assignee: Eli Lilly and CompanyInventors: David Andrew Coates, Craig Daniel Wolfangel
-
Patent number: 10080759Abstract: A method of treating pruritus (itching) in a subject in need thereof is carried out by administering the subject an active agent in a treatment effective amount, wherein the active agent is a superoxide dismuate (SOD) mimetic. The SOD mimetic can be a complex of a metal (e.g., manganese) and an organic ligand, with suitable organic ligands including porphyrins, polyamines, salens, nitroxides, and fullerenes. Compositions for carrying out such methods are also described.Type: GrantFiled: January 21, 2015Date of Patent: September 25, 2018Assignees: Duke University, BioMimetix J.V., LLCInventors: Ru-Rong Ji, Tong Liu, Ines Batinic-Haberle, David S. Warner, Kimberly C. Stone, James D. Crapo
-
Patent number: 10080760Abstract: The present invention provides compositions and methods for providing sustained release of an active agent through the skin of a subject, wherein a pharmaceutical percutaneous composition comprises at least one fatty acid ester and a therapeutically effective amount of active agent.Type: GrantFiled: October 26, 2010Date of Patent: September 25, 2018Assignee: BESINS HEALTHCARE LUXEMBOURG SARLInventors: Valerie Masini-Eteve, Denis Canet
-
Patent number: 10080761Abstract: The invention relates to medicine and specifically to methods for treating recurring forms of diseases related to the family of herpes viruses. A method for treating recurring diseases of the skin and mucous membranes caused by HSV-1 and HSV-2 involves applying a preparation to an affected area, said preparation including a base containing 0.5% or 1% of an active substance, namely a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula (I): where X is Na, K, NH4; the preparation is applied twice daily for 3-5 days and, should prodromes appear, a second course of treatment is carried out, in which the preparation is applied 1-2 times daily for 2-3 days; the base containing the active substance can be in the form of a cream, an ointment, a gel, a suspension, suppositories, a patch or a film.Type: GrantFiled: August 14, 2017Date of Patent: September 25, 2018Inventors: Viktor Veniaminovich Tets, Georgy Viktorovich Tets
-
Patent number: 10080762Abstract: Disclosed herein is a pharmaceutical composition comprising pharmaceutical formulation of complexed Celecoxib and crystalline Celecoxib to provide fast and long lasting continuous pain management with once a daily dosing. The pharmaceutical composition has improved physicochemical properties that provide faster onset of action for acute pain relief and lower GI related side effects for acute pain relief and lower GI related side effects.Type: GrantFiled: December 13, 2017Date of Patent: September 25, 2018Assignee: Druggability Technologies IP Holdco LimitedInventors: Richárd Balázs Kárpáti, Nikoletta Erdősi, Gergo Patyi, Hristos Glavinas, Genovéva Filipcsei
-
Patent number: 10080763Abstract: The described invention provides a topical bioadhesive film-forming pharmaceutical composition formulated for application directly to skin or to a substrate. The composition includes a therapeutic amount of an active agent; and one or more excipients selected from the group consisting of a non-cellulosic polymer or copolymer, a film forming agent, a plasticizer, a permeation enhancer, an antioxidant, a preservative, a solubilizer, a phase transfer catalyst, a viscosity modifier, a vitamin, a mineral nutrient, a solvent, a colorant and a fragrance. It further provides a delivery system comprising the composition and a means for administering the composition. It also describes uses of the delivery system in the manufacture of a medicament for treating a skin condition, disease or disorder, and a method for treating a skin condition, disease or disorder with the composition. The composition is characterized by: controlled release.Type: GrantFiled: August 17, 2015Date of Patent: September 25, 2018Assignee: SIDMAK LABORATORIES (INDIA) PVT. LTD.Inventors: Vinayak T. Bhalani, Anjan Kumar Paul, Ashim Kumar Sarkar
-
Patent number: 10080764Abstract: Topical minocycline compositions with reduced fluorescence are provided. In some instances, the compositions include an amount of a minocycline active agent associated with porous calcium particles. Also provided are methods of using the compositions, e.g., in the treatment of acne.Type: GrantFiled: December 15, 2016Date of Patent: September 25, 2018Assignee: Laboratory Skin Care, Inc.Inventor: Zahra Mansouri
-
Patent number: 10080765Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.Type: GrantFiled: September 20, 2017Date of Patent: September 25, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau